(Albany, US) DelveInsight launched a new report on Critical Limb Ischemia Market Insights, Epidemiology and Market Forecast-2030

 

DelveInsight’s “Critical Limb Ischemia – Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Critical Limb Ischemia , historical and forecasted epidemiology as well as the Critical Limb Ischemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Some of the key facts of the report

1. The prevalence of Critical Limb Ischemia is 12% in the adult population.
2. Critical Limb Ischemia account for only between 1% and 3% of all patients with PAD, with an incidence of between 500 and 1000 per million persons per year in Europe and North America.
3. It is estimated that there are approximately 2 million total Critical Limb Ischemia patients in the United States.

 

Key benefits of the report

1. Critical Limb Ischemia market report covers a descriptive overview and comprehensive insight of the Critical Limb Ischemia epidemiology and Critical Limb Ischemia market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Critical Limb Ischemia market report provides insights into the current and emerging therapies.
3. Critical Limb Ischemia market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Critical Limb Ischemia market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Critical Limb Ischemia market.

 

Request for sample pages : https://www.delveinsight.com/sample-request/critical-limb-ischemia-market

 

” According to Delveinsight, males are affected more as compared to females, in case of Critical Limb Ischemia.”

 

Critical Limb Ischemia (CLI) is a severe obstruction of the arteries which markedly reduces blood flow to the extremities (hands, feet, and legs) and has progressed to the point of severe pain and even skin ulcers or sores. The pain caused by CLI can wake up an individual at night. This pain, also called “rest pain”, is often in the leg and can be relieved temporarily by hanging the leg over the bed or getting up to walk around.

CLI is a very severe condition of peripheral artery disease (PAD) and needs comprehensive treatment by a vascular surgeon or vascular specialist. It is the advanced stage of peripheral artery disease (PAD), which results from a progressive thickening of an artery’s lining (caused by a buildup of plaque). This buildup of plaque, also known as atherosclerosis, narrows or blocks blood flow, reducing circulation of blood to the legs, feet, or hands.

The risk factors for critical limb ischemia include Age (Men over 60 and women after menopause),

Smoking, Diabetes, Overweight or obesity, High cholesterol, High blood pressure.

 

The launch of the emerging therapies is expected to significantly impact Critical Limb Ischemia treatment scenario in the upcoming years:-
Drugs covered:

1. AAV-hTERT
2. ACP-01
3. PLX-PAD
4. CLBS12

And many others

The key players in Critical Limb Ischemia market are:

1. Libella Gene Therapeutics
2. Hemostemix
3. Pluristem
4. Caladrius Biosciences
   And many others

 

Request for sample pages : https://www.delveinsight.com/sample-request/critical-limb-ischemia-market

 

Table of contents
1. Report Introduction

2. Executive Summary

3. SWOT Analysis

4. Critical Limb Ischemia Market Overview at a Glance

4.1. 7 Major Market Size of Critical Limb Ischemia in 2017

4.2. 7 Major Market Size of Critical Limb Ischemia in 2030

5. Disease Background and Overview: Critical Limb Ischemia

5.1. Introduction

5.2. Causes

5.3. Pathophysiology

5.4. Symptoms

5.5. Risk Factor

5.6. Diagnosis

6. Epidemiology and Patient Population

6.1. Assumptions and Rationale

6.2. 7MM Prevalent cases of Critical Limb Ischemia (2017–2030)

6.3. 7MM Grade-specific Prevalence of Critical Limb Ischemia (2017–2030)

6.4. 7MM Age-specific Prevalence of Critical Limb Ischemia (2017–2030)

6.5. 7MM Gender-specific Prevalence of Critical Limb Ischemia (2017–2030)

6.6. 7MM Diagnosed and Treatable Cases of Critical Limb Ischemia (2017–2030)

7. Critical Limb Ischemia: Country- Wise Epidemiology

7.1. United States

7.1.1. Prevalent cases of Critical Limb Ischemia in the United States (2017–2030)

7.1.2. Grade-specific Prevalence of Critical Limb Ischemia in the United States (2017–2030)

7.1.3. Age-specific Prevalence of Critical Limb Ischemia (2017–2030)

7.1.4. Gender-specific Prevalence of Critical Limb Ischemia in the United States (2017–2030)

7.1.5. Diagnosed and Treatable Cases of Critical Limb Ischemia in the United States (2017–2030)

7.2. EU-5

7.2.1. Germany

7.2.1.1. Prevalent cases of Critical Limb Ischemia in Germany (2017–2030)

7.2.1.2. Grade-specific Prevalence of Critical Limb Ischemia in Germany (2017–2030)

7.2.1.3. Age-specific Prevalence of Critical Limb Ischemia in Germany (2017–2030)

7.2.1.4. Gender-specific Prevalence of Critical Limb Ischemia in Germany (2017–2030)

7.2.1.5. Diagnosed and Treatable Cases of Critical Limb Ischemia in Germany (2017–2030)

7.2.2. France

7.2.2.1. Prevalent cases of Critical Limb Ischemia in France (2017–2030)

7.2.2.2. Grade-specific Prevalenceof Critical Limb Ischemia in France (2017–2030)

7.2.2.3. Age-specific Prevalence of Critical Limb Ischemia in France (2017–2030)

7.2.2.4. Gender-specific Prevalence of Critical Limb Ischemia in France (2017–2030)

7.2.2.5. Diagnosed and Treatable Cases of Critical Limb Ischemia in France (2017–2030)

7.2.3. Italy

7.2.3.1. Prevalent cases of Critical Limb Ischemia in Italy (2017–2030)

7.2.3.2. Grade-specific Prevalence of Critical Limb Ischemia in Italy (2017–2030)

7.2.3.3. Age-specific Prevalence of Critical Limb Ischemia in Italy (2017–2030)

7.2.3.4. Gender-specific Prevalence of Critical Limb Ischemia in Italy (2017–2030)

7.2.3.5. Diagnosed and Treatable Cases of Critical Limb Ischemia in Italy (2017–2030)

7.2.4. Spain

7.2.4.1. Prevalent cases of Critical Limb Ischemia in Spain (2017–2030)

7.2.4.2. Grade-specific Prevalence of Critical Limb Ischemia in Spain (2017–2030)

7.2.4.3. Age-specific Prevalence of Critical Limb Ischemia in Spain (2017–2030)

7.2.4.4. Gender-specific Prevalence of Critical Limb Ischemia in Spain (2017–2030)

7.2.4.5. Diagnosed an Treatable Cases of Critical Limb Ischemia in Spain (2017–2030)

7.2.5. United Kingdom

7.2.5.1. Prevalent cases of Critical Limb Ischemia in the United Kingdom (2017–2030)

7.2.5.2. Grade-specific Prevalence of Critical Limb Ischemia in the United Kingdom (2017–2030)

7.2.5.3. Age-specific Prevalence of Critical Limb Ischemia in the United Kingdom (2017–2030)

7.2.5.4. Gender-specific Prevalence of Critical Limb Ischemia in the United Kingdom (2017–2030)

7.2.5.5. Diagnosed and Treatable Cases of Critical Limb Ischemia in Spain (2017–2030)

7.3. Japan

7.3.1. Prevalent cases of Critical Limb Ischemia in Japan (2017–2030)

7.3.2. Grade-specific Prevalence of Critical Limb Ischemia in Japan (2017–2030)

7.3.3. Age-specific Prevalence of Critical Limb Ischemia in Japan (2017–2030)

7.3.4. Gender-specific Prevalence of Critical Limb Ischemia in Japan (2017–2030)

7.3.5. Diagnosed and Treatable Cases of Critical Limb Ischemia in Spain (2017–2030)

8. Treatment & Medical Practices

8.1. Treatment Algorithm

8.2. Treatment Guidelines

9. Patient Journey

10. Key Emerging Therapies

10.1. AAV-hTERT: Libella Gene Therapeutics

10.1.1. Regulatory Milestones

10.1.2. Clinical Development

10.1.3. Product Profile

10.1.4. Clinical Pipeline Activity

10.1.5. Ongoing Trials Information

10.1.6. Clinical Trial by Phase

10.2. ACP-01: Hemostemix

10.2.1. Regulatory Milestones

10.2.2. Clinical Development

10.2.3. Product Profile

10.2.4. Clinical Pipeline Activity

10.2.5. Ongoing Trials Information

10.2.6. Clinical Trial by Phase

To be continued in the report………

11. Attribute Analysis

12. Critical Limb Ischemia: Market Size

12.1. Key Findings

12.2. Total 7MM Critical Limb Ischemia Market Analysis

12.2.1. Overview of Total Critical Limb Ischemia Market

12.2.2. Market size of Critical Limb Ischemia by 7MM (2017–2030)

13. 7MM Critical Limb Ischemia: Country-Wise Market Analysis

13.1. United States

13.1.1. Total Market Size of Critical Limb Ischemia

13.1.2. Market Size of Critical Limb Ischemia by Therapies

13.2. Germany

13.2.1. Total Market Size of Critical Limb Ischemia

13.2.2. Market Size of Critical Limb Ischemia by Therapies

13.3. France

13.3.1. Total Market Size of Critical Limb Ischemia

13.3.2. Market Size of Critical Limb Ischemia by Therapies

13.4. United Kingdom

13.4.1. Total Market Size of Critical Limb Ischemia

13.4.2. Market Size of Critical Limb Ischemia by Therapies

13.5. Spain

13.5.1. Total Market Size of Critical Limb Ischemia

13.5.2. Market Size of Critical Limb Ischemia by Therapies

13.6. Italy

13.6.1. Total Market Size of Critical Limb Ischemia

13.6.2. Market Size of Critical Limb Ischemia by Therapies

13.7. Japan

13.7.1. Total Market Size of Critical Limb Ischemia

13.7.2. Market Size of Critical Limb Ischemia by Therapies

14. Market Access and Reimbursement

15. Market Drivers

16. Market Barriers

17. Appendix

18. Report Methodology

18.1. Sources Used

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

                                          
Related Reports:

 Critical Limb Ischemia – Pipeline Insights, 2020

The Critical Limb Ischemia report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Critical Limb Ischemia across the complete product development cycle, including all clinical and nonclinical stages.

Critical Limb Ischemia – Epidemiology Forecast to 2030

The Critical Limb Ischemia epidemiology covered in the report provides historical as well as forecasted Critical Limb Ischemia epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/